ULC0515T_S15
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.370
- WNT_BETA_CATENIN_SIGNALING+0.340
- APICAL_JUNCTION+0.330
- UV_RESPONSE_DN+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- MYOGENESIS+0.270
- NOTCH_SIGNALING+0.220
- BILE_ACID_METABOLISM+0.180
- COAGULATION+0.170
- CHOLESTEROL_HOMEOSTASIS+0.140
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.530
- G2M_CHECKPOINT-0.390
- MTORC1_SIGNALING-0.340
- E2F_TARGETS-0.310
- TNFA_SIGNALING_VIA_NFKB-0.310
- MYC_TARGETS_V2-0.290
- IL6_JAK_STAT3_SIGNALING-0.280
- PROTEIN_SECRETION-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613781 | — | A | 0.863 |
| 2 | TCGA-BH-A0HQ-01A-11R-A034-07 | — | B | 0.841 |
| 3 | GSM5359429 | — | — | 0.828 |
| 4 | TCGA-CV-7103-01A-21R-2016-07 | — | — | 0.821 |
| 5 | BSR_08_0188_C3_S52 | — | A | 0.811 |
| 6 | R208 | — | — | 0.801 |
| 7 | SRR26320067 | — | — | 0.799 |
| 8 | SRR8613703 | — | D | 0.799 |
| 9 | 563e85fb-9532-4d69-a1b5-2bc77f237b77 | — | — | 0.796 |
| 10 | TCGA-HN-A2OB-01A-21R-A27Q-07 | — | A | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.340 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |